|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ferlay J, Parkin DM and Steliarova-Foucher
E: Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 46:765–781. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carroll PR: Early stage prostate cancer-do
we have a problem with over-detection, overtreatment or both? J
Urol. 173:1061–1062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boehm K, Schiffmann J, Tian Z, Lesmana H,
Larcher A, Mandel P, Karakiewicz PI, Graefen M, Schwarz R, Krüll A
and Tilki D: Five-year biochemical recurrence-free and overall
survival following high-dose-rate brachytherapy with additional
external beam or radical prostatectomy in patients with clinically
localized prostate cancer. Urol Oncol. 34:119.e11–e18. 2016.
View Article : Google Scholar
|
|
6
|
Ishizaki F, Hara N, Koike H, Kawaguchi M,
Tadokoro A, Takizawa I, Nishiyama T, Takahashi K and Hohenfellner
R: Prediction of pathological and oncological outcomes based on
extended prostate biopsy results in patients with prostate cancer
receiving radical prostatectomy: A single institution study. Diagn
Pathol. 7:682012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Velonas VM, Woo HH, dos Remedios CG and
Assinder SJ: Current status of biomarkers for prostate cancer. Int
J Mol Sci. 14:11034–11060. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moyer VA: U.S. Preventive Services Task
Force: Screening for prostate cancer: U.S. Preventive Services Task
Force recommendation statement. Ann Intern Med. 157:120–134. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dabir PD, Ottosen P, Hoyer S and
Hamilton-Dutoit S: Comparative analysis of three- and two-antibody
cocktails to AMACR and basal cell markers for the
immunohistochemical diagnosis of prostate carcinoma. Diagn Pathol.
7:812012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Humphrey PA and Vollmer RT: Percentage
carcinoma as a measure of prostatic tumor size in radical
prostatectomy tissues. Mod Pathol. 10:326–333. 1997.PubMed/NCBI
|
|
11
|
Friedman RC, Farh KK, Burge CB and Bartel
DP: Most mammalian mRNAs are conserved targets of microRNAs. Genome
Res. 19:92–105. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li J, Ju J, Ni B and Wang H: The emerging
role of miR-506 in cancer. Oncotarget. Aug 15–2016.(Epub ahead of
print).
|
|
13
|
Pallante P, Visone R, Ferracin M, Ferraro
A, Berlingieri MT, Troncone G, Chiappetta G, Liu CG, Santoro M,
Negrini M, et al: MicroRNA deregulation in human thyroid papillary
carcinomas. Endocr Relat Cancer. 13:497–508. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohtsuka M, Ling H, Doki Y, Mori M and
Calin GA: MicroRNA processing and human cancer. J Clin Med.
4:1651–1667. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhai J, Qu S, Li X, Zhong J, Chen X, Qu Z
and Wu D: miR-129 suppresses tumor cell growth and invasion by
targeting PAK5 in hepatocellular carcinoma. Biochem Biophys Res
Commun. 464:161–167. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xiao Y, Li X, Wang H, Wen R, He J and Tang
J: Epigenetic regulation of miR-129-2 and its effects on the
proliferation and invasion in lung cancer cells. J Cell Mol Med.
19:2172–2180. 2015.PubMed/NCBI
|
|
17
|
Malik AY and Foster C: The revised
declaration of Helsinki: Cosmetic or real change? J R Soc Med.
109:184–189. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miah S, Ahmed HU, Freeman A and Emberton
M: Does true Gleason pattern 3 merit its cancer descriptor? Nat Rev
Urol. 13:541–548. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xu S, Yi XM, Zhou WQ, Cheng W, Ge JP and
Zhang ZY: Downregulation of miR-129 in peripheral blood mononuclear
cells is a diagnostic and prognostic biomarker in prostate cancer.
Int J Clin Exp Pathol. 8:14335–14344. 2015.PubMed/NCBI
|
|
20
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang QY, Tang J, Zhou CX and Zhao Q: The
down-regulation of miR-129 in breast cancer and its effect on
breast cancer migration and motility. Sheng Li Xue Bao. 64:403–411.
2012.(In Chinese). PubMed/NCBI
|
|
22
|
Wilson HC, Shah SI, Abel PD, Price P,
Honeyfield L, Edwards S and Abel RL: Contemporary hormone therapy
with LHRH agonists for prostate cancer: Avoiding osteoporosis and
fracture. Cent European J Urol. 68:165–168. 2015.PubMed/NCBI
|
|
23
|
Mapelli P and Picchio M: Initial prostate
cancer diagnosis and disease staging-the role of choline-PET-CT.
Nat Rev Urol. 12:510–518. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Molitierno J, Evans A, Mohler JL, Wallen
E, Moore D and Pruthi RS: Characterization of biochemical
recurrence after radical prostatectomy. Urol Int. 77:130–134. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Montironi R, Mazzuccheli R, Scarpelli M,
Lopez-Beltran A, Fellegara G and Algaba F: Gleason grading of
prostate cancer in needle biopsies or radical prostatectomy
specimens: Contemporary approach, current clinical significance and
sources of pathology discrepancies. BJU Int. 95:1146–1152. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hua X, Yu L, Pan W, Huang X, Liao Z, Xian
Q, Fang L and Shen H: Increased expression of Golgi
phosphoprotein-3 is associated with tumor aggressiveness and poor
prognosis of prostate cancer. Diagn Pathol. 7:1272012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Jonsson L, Gaber A, Ulmert D, Uhlén M,
Bjartell A and Jirström K: High RBM3 expression in prostate cancer
independently predicts a reduced risk of biochemical recurrence and
disease progression. Diagn Pathol. 6:912011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Diao Y, Wu D, Dai Z, Kang H, Wang Z and
Wang X: Prognostic value of transformer 2β expression in prostate
cancer. Int J Clin Exp Pathol. 8:6967–6973. 2015.PubMed/NCBI
|
|
29
|
Sempere LF: Integrating contextual miRNA
and protein signatures for diagnostic and treatment decisions in
cancer. Expert Rev Mol Diagn. 11:813–827. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo
J, Wang Y and Xu Y: miR-188-5p inhibits tumour growth and
metastasis in prostate cancer by repressing LAPTM4B expression.
Oncotarget. 6:6092–6104. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Spahn M, Kneitz S, Scholz CJ, Stenger N,
Rüdiger T, Ströbel P, Riedmiller H and Kneitz B: Expression of
microRNA-221 is progressively reduced in aggressive prostate cancer
and metastasis and predicts clinical recurrence. Int J Cancer.
127:394–403. 2010.PubMed/NCBI
|
|
32
|
Haflidadóttir BS, Larne O, Martin M,
Persson M, Edsjö A, Bjartell A and Ceder Y: Upregulation of miR-96
enhances cellular proliferation of prostate cancer cells through
FOXO1. PloS One. 8:e724002013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Fesler A, Zhai H and Ju J: miR-129 as a
novel therapeutic target and biomarker in gastrointestinal cancer.
Onco Targets Ther. 7:1481–1485. 2014.PubMed/NCBI
|
|
34
|
Tsai KW, Wu CW, Hu LY, Li SC, Liao YL, Lai
CH, Kao HW, Fang WL, Huang KH, Chan WC and Lin WC: Epigenetic
regulation of miR-34b and miR-129 expression in gastric cancer. Int
J Cancer. 129:2600–2610. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bandres E, Agirre X, Bitarte N, Ramirez N,
Zarate R, Roman-Gomez J, Prosper F and Garcia-Foncillas J:
Epigenetic regulation of microRNA expression in colorectal cancer.
Int J Cancer. 125:2737–2743. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen X, Zhang L, Zhang T, Hao M, Zhang X,
Zhang J, Xie Q, Wang Y, Guo M, Zhuang H and Lu F:
Methylation-mediated repression of microRNA 129-2 enhances
oncogenic SOX4 expression in HCC. Liver Int. 33:476–486. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen X, Ruan A, Wang X, Han W, Wang R, Lou
N, Ruan H, Qiu B, Yang H and Zhang X: miR-129-3p, as a diagnostic
and prognostic biomarker for renal cell carcinoma, attenuates cell
migration and invasion via downregulating multiple
metastasis-related genes. J Cancer Res Clin Oncol. 140:1295–1304.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dyrskjot L, Ostenfeld MS, Bramsen JB,
Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL,
Andersen CL, Zieger K, et al: Genomic profiling of microRNAs in
bladder cancer: miR-129 is associated with poor outcome and
promotes cell death in vitro. Cancer Res. 69:4851–4860. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Goździk-Spychalska J, Szyszka-Barth K,
Spychalski L, Ramlau K, Wójtowicz J, Batura-Gabryel H and Ramlau R:
C-MET inhibitors in the treatment of lung cancer. Curr Treat
Options Oncol. 15:670–682. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Duan L, Hao X, Liu Z, Zhang Y and Zhang G:
MiR-129-5p is down-regulated and involved in the growth, apoptosis
and migration of medullary thyroid carcinoma cells through
targeting RET. FEBS Lett. 588:1644–1651. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Yang Y, Pan X, Lei W, Wang J, Shi J, Li F
and Song J: Regulation of transforming growth factor-beta 1-induced
apoptosis and epithelial-to-mesenchymal transition by protein
kinase A and signal transducers and activators of transcription 3.
Cancer Res. 66:8617–8624. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bao B, Ahmad A, Kong D, Ali S, Azmi AS, Li
Y, Banerjee S, Padhye S and Sarkar FH: Hypoxia induced
aggressiveness of prostate cancer cells is linked with deregulated
expression of VEGF, IL-6 and miRNAs that are attenuated by CDF.
PloS One. 7:e437262012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Abukhdeir AM and Park BH: P21 and p27:
Roles in carcinogenesis and drug resistance. Expert Rev Mol Med.
10:e192008. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Fu M, Wang C, Li Z, Sakamaki T and Pestell
RG: Minireview: Cyclin D1: Normal and abnormal functions.
Endocrinology. 145:5439–5447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hashimoto Y, Naruyama H, Ando R, Okada S,
Tozawa K and Kohri K: Molecular targeted therapy for prostate
cancer. Hinyokika Kiyo. 54:57–61. 2008.PubMed/NCBI
|
|
46
|
Lee JT, Lehmann BD, Terrian DM, Chappell
WH, Stivala F, Libra M, Martelli AM, Steelman LS and McCubrey JA:
Targeting prostate cancer based on signal transduction and cell
cycle pathways. Cell Cycle. 7:1745–1762. 2008. View Article : Google Scholar : PubMed/NCBI
|
